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Interspecies Comparisons of Tissue DNA
Damage, Repair, Fixation, and Replication
by Thomas J. Slaga*
The many anatomical, physiological, and biochemical differences among various mammalian species
make it difficult to extrapolate carcinogenic potency data from animals to humans. The process is further
complicatedbythemultisteporiginofmostmalignant tumors inanimalsandhumansduetothe interaction
of target cells with both endogenous and exogenous factors. Species differences in these aspects of car-
cinogenesis must also be considered when attempting to evaluate the carcinogenic risks of chemicals to
humans. Cancer development in animals involves at least three distinct stages: initiation, promotion, and
progression. Intra- and interspecies differences in susceptibility to carcinogenesis may be related to any
one or a combination of these stages. Variation in species susceptibility to tumor initiation may result
from differences in the abilities of various species to metabolize a potential carcinogen to an ultimate
carcinogenic form and/or to detoxify the carcinogen. Most comparative studies among species have only
revealed subtle differences in metabolism.
DNA adducts from several activated carcinogens have been found to be the same in a number oftissues
from various species, including humans. Capacity for DNA repair is apparently a critical factor in the
initiation of carcinogenesis in target cells of different species but is less critical among mice that differ
in susceptibility to two-stage carcinogenesis ofthe skin and liver. Susceptibility variations among stocks
and strains to such carcinogenesis appear to be related to alterations in tumor promotion. Additional
comparative studies are critically needed on all aspects ofcarcinogenesis to permit effective extrapolation
of carcinogenic potency data from animals to humans.
Introduction
Epidemiological data and studies with experimental
animals have provided important clues that chemicals
in ourenvironment are responsible for asignificant por-
tion of human cancer (1,2). Although there are many
natural and synthetic chemicals that induce cancer in
experimental animals, it is very difficult to determine
their possible activity in humans because no epide-
miological data exist (3-5). The many anatomical, phys-
iological, andbiochemical differences amongthe various
mammalian species make it very difficult to extrapolate
carcinogenic potency datafromexperimental animals to
humans. The development of cancer in humans appears
to involve at least three distinct stages: initiation, pro-
motion, and progression. Intra- and interspecies differ-
ences in susceptibility to carcinogenesis may be related
to any one or a combination of these stages.
Although many species differences have been found
in response to chemical carcinogens and/or tumor pro-
moters, there have been few critical investigations of
this subject. In most instances the studies were not
designed forrigorous comparative analysis. Differences
wereoftennotedonly asinterestingsidelights ofastudy
that did not focus primarily upon comparative aspects.
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Furthermore, for obvious reasons, human data are only
obtained from epidemiological studies or from in vitro
studies with human tissues or cells. Currently, very
little is known about what determines carcinogenic po-
tency, organ specificity, or species specificity. In some
cases, differences in metabolic activation and/or detox-
ification, differential rates ofrepair ofspecific DNA ad-
ducts, tumor promotion, or cofactor interactions have
been found and associated with organ and species spec-
ificity (3-5). The detailed comparative biochemistry of
the mechanisms underlying these differences is poorly
understood, however, and there should be extensive
investigations in order to eliminate this gap in our
knowledge.
It is not the intent of this paper to present an ex-
haustive review on the comparison oftissue damage by
carcinogens in various species and the subsequent re-
pair, fixation, and replication processes, but only to
highlight the known critical events and factors that ap-
pear to be associated with species differences in mul-
tistage chemical carcinogenesis.
Species Differences in
Carcinogenesis
A wide variety ofchemicals are known to induce ma-
lignant tumors in experimental animals, especially inT. J. SLAGA
rodents, and to a lesser degree in nonhuman primates.
The focus of this paper will be to describe the effects
of two classes of chemicals, polycylic aromatic hydro-
carbons (PAHs) and nitrosamines. Many compounds in
these classes, as well as many other carcinogens, are
considered indirect carcinogens because they must be
metabolically activated (1). Inasmuch as metabolic ac-
tivation of chemical carcinogens appears to be one of
the important factors in species differences, especially
related to quantitative differences but not necessarily
to qualitative differences, attention will be given to this
category of chemicals (5).
Direct-acting carcinogens are also an important cat-
egory of chemicals that are highly reactive. Insofar as
carcinogens in this category have been tested, they
show fewer species differences (5). Carcinogenicity and
organ specificity ofdirect-acting carcinogens are highly
dependent ontherouteofadministrationand areusually
active at the site of application (6).
Table 1 summarizes the response of several species
to carcinogenic PAHs, nitrosamines and nitrosamides,
aromatic amines, and mycotoxins. As indicated in Table
1, each of these agents is responsible for some form of
tumor development with little qualitative difference be-
tween species. Although there have only been a few
comparative studies with mycotoxins, there also ap-
pears to be little qualitative difference in tumor re-
sponse forthe species that have been studied; however,
these studies have shown quantitative differences in
tumor response, the organs affected, specific charac-
teristics ofthe carcinogen, and the route ofadministra-
tion (3,5).
In terms of PAH carcinogens, species differences
were observed when PAHs were given either SC or
topically (3). As shown in Table 2, the rat and fowl were
found to respond positively to subcutaneous carcino-
genesis but poorly to skin carcinogenesis, whereas the
rabbit showed the opposite response (3). The mouse is
very sensitive to tumor induction, the hamster is only
moderately responsive to either route, and the guinea
pigispoorlyresponsive toeitherrouteofadministration
(3). Benzo[a]pyrene (BP), dibenz[a,h]anthracene
Table 1. The response of different species to various
classes of carinogens.a
Carcinogen
Poycyclic Nitrosamines
aromatic and Aromatic Mycotoxins
Species hydrocarbons nitrosamides amines (aflatoxin B1)
Mouse + + + +
Rat + + + +
Hamster + + +
Guinea pig + + +
Rabbit + + +
Dog + + +
Monkey +/- + +/- +
Man +/- +1- +1- +1-
a(+) Represents a carcinogenic response by at least one member
ofaclass ofcompounds in some tissue ofagivenspecies; (+/-) refers
to a borderline effect or insufficient data. Refer to Tables 2 and 4 for
differences incarcinogensfromagivenclassandfororgandifferences.
Table 2. The response of different species to the carcinogenic
action of polycyclic aromatic hydrocarbons (3).
Route of administration
Species Skin painting SC injection
Mouse + + + + + + + + + +
Rabbit ++++ +
Rat ++ ++++++
Guinea pig + +a + +b
Hamster + + + a + + +
Fowl + + + + + +
Dogc + + ?+
Man'Cd + + + ?7
aHigh proportion ofmelanomas.
bHigh proportion of liposarcomas.
'Very long latent period (7 years or more).
dRefers to carcinogenic tars, mineral oils, waxes, etc., as no in-
formation is available with reference to pure hydrocarbons.
(DBA), and 3-methylcholanthrene (MC) were found to
be negative in Old and New World monkeys (7), but
MC and BP were active in more primitive primates (8).
Although pure PAHs have not been directly related to
human cancer, there is suggestive evidence that petro-
leum tars, mineral oils, and waxes are active (3). As
shown in Table 3, the various stocks and strains ofmice
also have different responses to skin carcinogenesis by
PAH but to a lesser degree than among the various
species listed in Table 2 (9).
Although they induce tumors of different cell types
and in different organs among species, as a group the
nitrosamines are carcinogenic in all species examined
(10,11). This variability in organ specificity for nitro-
samines is probably due to species differences in routes
of metabolism and activation (10). Table 4 summarizes
the various species differences and organ specificity for
nitrosamines. Both dimethylnitrosamine (DMN) and di-
ethylnitrosamine (DEN) are potent liver carcinogens in
all species examined (Table 4). More than likely, these
compounds are also liver carcinogens in man, consid-
ering that in all species examined they are metabolized
in a similar manner, give the same adducts, and lead to
similar hepatotoxicity (10-12). Furthermore, many dif-
ferent types of nitrosamines (e.g., symmetrical and
asymmetrical nitrosodialkylamines and cyclic nitrosa-
mines) have been found to be carcinogenic in a number
of different species (10).
The route of administration appears to be an impor-
tant consideration for nitrosamine toxicity. In general,
the nitrosamines can be considered systemic carcino-
Table 3. Sensitivity to skin carcinogenesis in different stocks
and strains of mice (9)Wa
Complete carcinogenesis
Sencar > CD-1 > C57BL/6 a BALB/c a 1CR/Ha Swiss > C3H
Two-stage carcinogenesis (initiation-promotion)
Sencar > CD-1 > ICR/Ha Swiss > BALB/c a C57BL/6 a C3H a
DBA/2
aData represent sensitivities tobenzo[a]pyrene and dimethylbenz-
anthracene. Ranking represents a subjective analysis because dose-
response data were not available for many strains.
74CARCINOGENESIS AND INTERSPECIES COMPARISON
Table 4. The carcinogenicityof some representative nitrosamines in various species.'
Nasal
Compound Species Liver Kidney Esophagus Lung sinuses Stomach Bladder Brain Skin
Dimethylnitrosamine (DMN) Rat + + + + + ++ (?)
Mouse + + + + + +
Hamster + +
Guinea pig +
Trout +
Diethylnitrosamine (DEN) Rat + + + + + + +
Mouse + + + + + +
Hamster + + + +
Guinea pig + + + +
Rabbit +
Dog +
Monkey +
Trout +
Dibutylnitrosamine Rat + + + + + + +
Mouse + + + + + +
Hamster + + + + + + +
Methylphenylnitrosamine Rat + +
(N-methyl-N-nitroso-aniline) Mouse + +
N-nitrosomorpholine Rat + + + + + +
Mouse + + + + +
Hamster +
N-nitrosopiperidine Rat + ++ +++ +± ++ +
Hamster +
Mouse + +
N,N'-dinitrosopiperazine Rat + ++ + +
Mouse + + + +
N-methyl-N-nitrosourea Rat + + + + + + + + +++
Mouse + + +
N-methyl-N-nitrosourethane Rat + + + + + + + +
Mouse + + + + +
N-methyl-N-nitroso- Rat ++
N'nitroguanidine
Mouse + + ++ ++
Dog
aModified from Berenblum (3).
gens and not local carcinogens. However, those nitro-
samides that are direct-acting carcinogens are carcin-
ogenic at the site of application (6).
There are a number ofreasons that the nitrosamines
have become a matter of great concern in relation to
humancarcinogenesis. Thenitrosamines are quite prev-
alent in the human environment and can develop spon-
taneously in the stomach by the interaction oftwo non-
carcinogenic substances, secondaryamines and nitrites.
All species that have been tested are responsive to the
carcinogenic action of these compounds, strongly sug-
gesting that they are carcinogenic to humans, and, un-
der certain experimental conditions, a single dose can
be carcinogenic.
Several other classes ofcarcinogens such as aromatic
amines, hydrazines, and mycotoxins are carcinogenic in
several species ofanimals and maythus be carcinogenic
in humans. The liver and bladder are the most common
targets for a number of different aromatic amines in
various species (3,13). Epidemiological data also sug-
gest that certain aromatic amines are carcinogenic in
humans(1,13). Althoughdifferenthydrazineshavebeen
found to be carcinogenic in rats and mice, there have
not been many species comparison studies performed
with other species (3,5,14). Mycotoxins, such as afla-
toxinB1, arepotentcarcinogens in anumberofdifferent
species, including monkeys (7,15). Epidemiological
data, as well as data from several species showing sim-
ilarityofmetabolismandadductformation, suggestthat
aflatoxin B1 may be carcinogenic in humans (15).
Metabolic Activation of Chemical
Carcinogens to Electrophilic
Intermediates and DNA Binding
Millerand Miller (1) have proposed ageneralunifying
theory to explain the initial event in chemical carcino-
genesis. They state that all chemical carcinogens that
are not electrophilic reactants must be converted met-
abolically into chemically reactive electrophilic forms
which then react with some critical nucleophilic site(s)
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in macromolecules to initiate the carcinogenesis. As
there have been extensive species comparison studies
on the metabolic activation and DNA binding of many
types ofchemical carcinogens, this discussion will focus
on the metabolic activation and DNA binding of PAHs
and nitrosamines.
There is considerable evidence supporting the exis-
tence of many species-specific, organ-specific, and cell-
specific isozymic forms of the xenobiotic-transforming
enzymes responsible formetabolizing PAH carcinogens
(16,17). The carcinogenic PAHs are metabolized by the
microsomalmixed-function oxidase systemoftargettis-
sues to a variety of metabolites such as phenols, qui-
nones, epoxides, dihydrodiols, anddihydrodiol-epoxides
(17,18). As depicted in Figure 1, the major pathway of
activation ofBP leads to the formation ofa dihydrodiol-
epoxide ofBP, which interacts predominantly with the
2-amino of guanine of DNA (18,19). The dihydrodiol-
epoxide of BP appears to be the major ultimate muta-
genic and carcinogenic metabolite of BP (18,20,21).
Nevertheless, one should keep in mind that other me-
tabolites, such as certain phenols, epoxides, and qui-
nones, may contribute to the overall carcinogenic activ-
ity of BP (21). In addition, a free radical mechanism
may also be partly involved in its carcinogenic activity
(22).
In the case ofcarcinogenic PAHs, it appears that one
of the major determinants of carcinogenic potency re-
lates to the substrate specificity of the cytochrome P-
450 mixed-function oxidase system (23). The extent to
which a given parent PAH will be metabolized by the
P-450 system to a reactive dihydrodiol-epoxide may be
very critical with respect to carcinogenic potency. It
appears that benzo[e]pyrene is noncarcinogenic or
weakly carcinogenic because it is a poor P-450 system
substrate for activation to a dihydrodiol-epoxide or any
otherreactive intermediate (18). Anotherimportant de-
terminant ofcarcinogenic potency is related to the abil-
ity of various drug-metabolizing enzymes to detoxify
the carcinogen (16,17). The presence, as well as the
activities of metabolic activating and detoxifying en-
zymes, areimportantincarcinogenpotency, organspec-
ificity, and species differences (16-18).
Table 5 compares the metabolism of BP by cultured
tracheobronchial tissue from various species (24). As
Hepatic microsomal
R-CH2.N enzymes R-CH2..
R-CH2 0 Ca-C-hydroxylation R-CH .0 \YHeterolysis
R-CH2 R
R-CH N=N"'~~ ~ RCH
2-N-N=O Non-enzymatic R-CH2, L OH
I - -N=0 Diazohydroxide R-CH2-C=O dissociation H
+R-CH2-CHO Spontaneous
Tumorigenesis DNA? N2 + [R-CH+4.. [R-CH2.NuN+OH]
Alkyidlazonium
FIGURE 1. The major metabolic activation pathway of benzo-
[a]pyrene (BP) leading to its tumorigenic effect,
Table 5. Metabolism of benzo[a]pyrene (BP) by cultured
tracheobronchial tissues.'
Relative BP Ratio, organo- /
binding to Relative BP water-soluble
Species DNA, % metabolism, % metabolites
Human llblOOc 0.4
Rat
CD 41 10 0.2
Buffalo 47 10 0.2
Wistar 69 10 0.2
Mouse
C57BL/6N 34 16 1.4
DBA/2N 28 6 0.5
Hamster 81 21 1.2
aModified from Autrup et al. (24).
bThe human BP binding data (BP bound per 10 mg DNA) were set
at 100%, and the binding data from other species are relative to the
human data.
cThe human BPmetabolism data (BPmetabolized per 10mg DNA)
were set at 100%, and the metabolism data from the other species
are relative to the human data.
can be seen, human tracheobronchial tissue is more ef-
fective than that ofthe rat, mouse, and hamster in the
amount of BP metabolized, as well as in metabolizing
BPto specificreactive intermediates that bind to DNA.
Although there are quantitative differences in the var-
ious BP metabolites formed (e.g., phenols, quinones,
dihydrodiols, and epoxides) in any given tissue or cell
from various species, there are very few qualitative
differences (17). Similarly, thereisverylittle difference
even in terms of specific BP adducts to target tissue
DNA of various species, including humans (19,24). If
overall metabolism of BP and binding of BP to DNA
are indications of carcinogenic activity, then humans
wouldbe expected tobe more susceptibleto PAHsthan
mice, rats, or hamsters.
A number of studies have demonstrated a good cor-
relation between the carcinogenicity of several PAHs
and their ability to bind covalently with target tissue
DNA ofany given species (25,26). However, extensive
dose-response studies, as shown in Figure2, comparing
BP skin tumor initiating activity and DNA binding in
mice, have revealed adifference inthe saturation ofthe
tumorresponse and DNA binding (27). These data sug-
gest that to find a strong correlation between these
parameters, specific subpopulations of cells in a given
target tissue and/or specific genes such as oncogenes in
DNA for binding of the carcinogenic PAH should be
examined.
The nitrosamines and nitrosamides are another im-
portant class of chemicals, because a large number of
these compounds have been found to be carcinogenic.
Nitrosamines requiremetabolicactivationbytargettis-
sue microsomal mixed-function oxidases (10). Unlike
PAHs, nitrosamines require only the first activation
step, resulting in the formation of an hydroxylated in-
ternediate that is sufficiently unstable to decompose
spontaneously and generate a reactive carbonium ion.
Alkylation of intracellular target macromolecules such
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FIGURE 2. Semi-log plot of the dose-response relationships with
benzo[a]pyrene (BP) for tumor initiation and covalent binding to
DNA in mouse epidermis. For the tumor initiation experiments,
BP was applied (at various doses to the skins ofmice) as a single
topical application. One week after initiation, mice received twice
weekly applications of 3.4 nmole 12-O-tetradecanoylphorbol-13-
acetate (TPA) for 24 weeks. For the binding experiments, [3H]BP
was applied at various doses and mice were sacrificed 24 hr later.
The specific activity of [3H]BP used for each dose was as follows:
10 nmole, 1.1 x 10 dpm/pmole; 50 nmole, 2.2 x 104 dpm/pmole;
100 nmole, 1.1 x 104 dpm/pmole; 200 nmole, 5.5 x 103 dpm/pmole;
400 nmole, 2.75 x 103 dpm/pmole; 600 nmole, 1.83 x 103 dpm/
pmole; 800 nmole, 2.75 x 103 dpm/pmole; 1000 nmole, 2.2 x 103
dpm/pmole; and 1600 nmole, 1.38 x 103 dpm/pmole. Modified from
Ashurst et al. (27). (0) Average number ofpapillomas per mouse
at 24 weeks of promotion; (0) total covalent binding of [3H]BP
metabolites to epidermal DNA expressed as pmole/mg DNA; (l)
anti-BPDE bound to deoxyguanosine expressed as pmole/mg
DNA.
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FIGURE 3. Metabolic pathway of activation of nitrosamines and ni-
trosamides that may be responsible for their tumorigenic effect.
as DNA or proteins follows rapidly (Fig. 3). Although
the actual target site for nitrosamine carcinogenesis is
not fuliy understood, a number of alkylation sites in
DNA (e.g., 06-methylguanine, 7-methylguanine, and 3-
methyladenine) are known (12). In contrast, nitrosam-
ides do notrequire metabolic activation because oftheir
inherentchemicalinstabilityinaqueous solution(6). The
nitrosamides are converted nonenzymatically at phys-
iological pH to produce the same class ofreactive elec-
trophiles as those from the nitrosamines (Fig. 3).
N-Nitroso compounds are synthesized by reacting
dietary secondary amines with nitrous acid under the
naturally acidic conditions in the stomach (28). Nitrates
in food preservatives and food color enhancers are con-
vertedbygastricjuicetonitrosatingcompounds (28,29).
Carcinogenic nitrosamines induce tumors in different
organs in all species examined. The organ specificity of
nitrosamines appears to be related to differences in me-
tabolism and activation, but there is no clear under-
standing ofthis process. Ifone considers the nitrosam-
ides, which show some organ specificity but do not have
to be metabolized, the differences in susceptibility to
carcinogenesis cannot be ascribed only to differences in
metabolism (6). The rate ofremoval of specific adducts
appears to be important in organ and species differ-
ences.
Investigations suggest that metabolic activation and
DNA binding are important determinants in the car-
cinogenic activity ofaromatic amines and mycotoxins in
a number of different species. These adducts occur in
most species, including humans, at the C-8 position of
guanine (1,14). Aromatic amines possess reactive pri-
mary or secondary amine groups that are actively in-
volved in determining their carcinogenicity (1,13). The
metabolic activation of2-acetylaminofluorine (AAF) in-
volves N-hydroxylation (primarily at the C-8 position
ofguanine) followed by esterification formingareactive
carcinogen (1,14). Inadditiontointerspecies differences
in the ability to N-hydroxylate aromatic amines, there
appeartobeintraspecies differences aswell(1,30). Tak-
eishi et al. (31) have shown that in vitro guinea pig
tissues are capable of N-hydroxylating AAF, but this
is not seen in the intact animal. They suggested that
the resistance ofthe intact guinea pig is related to the
ability of this species to detoxify all of the activated
metabolite (31). Experimental evidence indicates that
aflatoxin B1 (AFB1) is metabolically activated to AFB1-
2,3-oxide, whichistheultimatereactivemetabolite (15).
The principal adduct of AFB1 formed with DNA in all
species examined is with the N-7 position of guanine
(15). Booth et al. (32) compared the binding ofAFB1 to
liver DNA from humans, rats, mice, and hamsters.
They found that the binding level followed the same
order as the potency ofAFB1 to induce liver cancer in
these species (i.e., rat > hamster > mouse). Inasmuch
as the bindinglevel ofAFB1 toliver DNAfromhumans
wasfoundtobebetweenthatofthehamsterandmouse,
itis suggested thathumans aremuchless sensitivethan
rats and are somewhat less sensitive than hamsters.
Table 6 summarizes the reaction with DNA of some
chemical carcinogens discussed in this paper and se-
lected examples of other carcinogens. There are many
different types and sites ofadduct formation with DNA
for these several classes ofcarcinogens. Evidence sug-
geststhatcertainadductssuchas 06-methylguanine are
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Table 6. Summary of reactions of some chemical carcinogens or their metabolites with nucleic acids.a
Carcinogenic agents
2-Acetylaminofluorene
Aflatoxin B1
Benzo[a]pyrene
cis-Diamminedichloroplatinum (II)
Safrole
Mustards
Difunctional
Monofunctional
1-Propiolactone
Alkyl sulfonates
Alkyl nitrosamides
Alkyl nitrosamidines
Dimethylnitrosamine
aModified from Friedberg (33).
Reactive intermediates
N-Hydroxylation followed by esterification
2,3-Oxide of aflatoxins
Dihydrodiol epoxide
Direct acting
Ester of i'-hydroxysafrole and/or 1'-hydroxy-
2',3' oxide of safrole
Direct acting
Direct acting
Direct acting
Direct acting
Direct acting (alkali catalyzed)
Direct acting (alkali or thiol catalyzed)
Oxidative demethylation: methyldiazonium
hydroxide
Sites of reaction in nucleic acids
C-8 of guanine; N-2 of guanine
N-7 of guanine; N-1, N-3 of adenine
N-2 of guanine; exocyclic amine
groups of adenine and cytosine
Cross-links from 0-6 of guanine to N-7 of
guanine
0-6 of guanine
Inter- and intrastrand cross-links in DNA; DNA-
protein cross-links
N-7, N-3, N-1 of adenine
N-7, N-3, N-1, 0-6 of guanine
N-1, N-3, 0-2 of cytosine
N-3, 0-4 of thymine
Phosphate esterification
important in carcinogenesis and mutagenesis, but there
is currently no definitive proof that any adduct(s) is
obligatory in the carcinogenesis process. There is, how-
ever, a reasonable degree of correlation between car-
cinogenicity and the extent of carcinogen binding to
DNA (1,25,26).
It is difficult to formulate a unified theory relating
specific types ofDNA damage to the mechanism of car-
cinogenesis, because adducts can react at multiple sites
or may form multiple types of adducts. There is evi-
dence that both major and minor DNA adducts formed
byactivated derivatives ofBP, AAF, AFB1, and certain
nitrosamines are the same in different target tissues of
various species, includinghumans (1,19,22). Table 7lists
several animal carcinogens that bind to DNA ofvarious
human tissues and in most cases form the same adducts
(24). These data strongly suggest that these compounds
are human carcinogens; however, there is variability in
the bindingdataobtained fromdifferent human subjects
(24,34) and it should be emphasized that some known
carcinogens do not interact to a detectable extent with
DNA (19,35).
DNA Repair, Fixation, and
Replication
The capability for DNA repair is an important de-
terminant of whether or not a cell becomes initiated.
Since many chemical carcinogens or their reactive me-
tabolites cause DNAdamage, animportantdeterminant
of whether a cell becomes initiated by a carcinogen is
DNA repair. Inhibition ofthe excision repair system or
a faulty repair system enhances the chance that the
carcinogenic damage will not be repaired, thus leading
to the irreversible, initiated carcinogenic state (36-38).
Inhibition of repair or induction of error-prone DNA
could also lead to a carcinogenic process (36,39). The
ability to repair DNA damage caused by both physical
and chemical carcinogens could have profound effects
on the susceptibility of various species to the induction
ofcancerby agivencarcinogen. Cleaverand co-workers
reported that human and monkey cells have a greater
rate ofexcisionrepairthan mouse cells (20). Thisfinding
suggests that mouse cells should be more susceptible to
chemical carcinogens than human and monkey cells,
based on several lines ofevidence, including: ease of in
vitro transformation of mouse cells, difficulty of onco-
Table 7. Chemical carcinogens activated to form DNA adducts by cultured human tissue.a
Carcinogen Bronchus Colon Esophagus Pancreatic duct Bladder
Benzo[a]pyrene + + + + +
7,12-Dimethylbenz[a]anthracene + + + +
Nitrosodimethylamine + + + +
Nitrosodiethylamine + + +
Nitrosopyrrolidine + +
Aflatoxin B1 + + + +
1,2-Dimethylhydrazine + + +
2-Acetylaminoflourene + + +
a(+) Carcinogen-DNA adducts were detected; (-) adducts not detected; no symbol, not tested. Modified from Autrup et al. (24).
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genic transformation of human cells in culture, and
greater cytotoxicity of mouse cells than human cells
(4,41).
The importance of DNA repair in carcinogenesis is
also suggested by the increased, if not invariable, in-
cidence ofcancer in people with hereditary DNA-repair
defects, such as xeroderma pigmentosum, Fanconi's
anemia, Bloom's syndrome, retinoblastoma, ataxia te-
langiectasia, and porokeratosis Mibelli (40,42). These
hypersensitivity diseases are associated with various
DNA repair defects and/or replication abnormalities,
e.g., a person with xeroderma pigmentosum has an in-
herited hypersensitivity to ultraviolet light which can
lead to skin cancer.
Three types of repairable DNA damage are known:
(a)missing, incorrect, or altered DNA bases; (b)in-
terstrand cross-links; and (c)strand breaks (37). DNA
repair in mammalian cells can occur by at least two
different processes, excision or postreplication repair
(36,37). The excision repair process has been exten-
sivelystudiedinrelation tocarcinogenesis. Table8 sum-
marizes repair by the removal of carcinogen-DNA ad-
ducts by DNA repair enzymes (37). Currently, very
little is known about the enzymatic mechanisms by
which BP-, AAF-, and aflatoxin-DNA adducts are re-
moved. Furthermore, little is known about the conse-
quences that persistent adducts (i.e., those that are not
repaired) have on DNA replication and gene transcrip-
tion in mammalian cells from various species (36,37).
The mutagenic and carcinogenic effects of nitrosa-
mines and nitrosamides have been associated with the
formation and persistence in DNA of 06-alkylguanine
adducts (12,43,44). Persistent04-alkylthyminehasbeen
implicated as a mutagenic and carcinogenic lesion
(37,43). Other DNA adducts, like 3-alkyladenine and 7-
alkylguanine, are rapidly removed by specific N-gly-
cosylases (37). The relative persistence of 06-alkyl-
guanine and possibly 04-alkylthymine adducts appears
to be related to organ and species differences in nitro-
samine and nitrosamide carcinogenesis (43). The nitro-
samines and nitrosamides are highly suspected to cause
human cancer because the same adducts areformed and
appear to persist in cultured human tissue (24).
As previously emphasized, there is a fairly good cor-
Table 8. Removal of carcinogen-DNA adducts by
DNA repair enzymes.a
Product Enzyme Adduct
Oligonucleotide, Endonuclease/ Thymine dimer, probably
nucleotide exonuclease aromatic amine,
polycyclic hydrocarbon,
etc.
Base DNA glycosylase/ 3-Methyladenine
exonuclease 7-Methylguanine
Uracil
Hypoxanthine
Adduct itself Adaptive enzyme, Methyl group
(06-methyl methyl
guanine) transferase
'Modified from Magee (37).
relation in any given species between the amount of
carcinogen bound to DNA and the tumor response
(1,19,26). Furthermore, for any individual stock or
strain of mouse, it has been generally observed that
there is an excellent correlation between the amount of
PAH bound to DNA and the skin tumor response (26).
However, this correlation between DNA binding and
tumor responsebreaksdownwhen acomparisonismade
between mouse strains or stocks that differ in their
tumor response to two-stage or to complete carcino-
genesis (9). Phillips et al. (45) have demonstrated that
the kinetics ofbindingofDMBAtothe DNAsofC57BL/
6, DBA/2, or Swiss mice were virtually identical in
terms of formation and removal of adducts with time
(Table9). Althoughthereisthepossibilitythat aspecific
metabolite ofthe DMBA was responsible for the tumor
response and was undetected in this study, recent in-
vestigations suggest that the major metabolites of
DMBAand BP arequalitatively similarin mouse strains
that vary in their response to two-stage or complete
carcinogenesis with PAHs (46). The kinetics of DMBA
binding to, and removal from, epidermal DNA in SEN-
CAR and CD-1 mice are also similar to the C57BL/6,
DBA/2, and Swiss strains ofmice (9,46). Althoughthese
data are far from conclusive, they suggest that some
aspects ofinitiation are probabaly similar in strains and
stocks ofmice that differ in their response to two-stage
or complete carcinogenesis.
Drinkwater and Ginsler (47) also reported that the
kinetics of DEN binding to liver DNA in two different
strains of mice were very similar, even though their
susceptibilities to DEN carcinogenicity were quite dif-
ferent. For example, when newborn male C57BL/6 and
C3H mice were injected with DEN (0.1 ,umole/g body
weight) the mean liver tumor incidences at 32 weeks
were 0.33 and 35 tumors per animal, respectively (47).
This suggests that the difference in susceptibility to
liver cancer by DEN is related to an event or events
after initiation, such as excision and repair.
Importance of Tumor Promotion in
Inter- and Intraspecies Differences
Most ofthedatathatsuggesttheimportance oftumor
promotion in the inter- and intraspecies differences in
carcinogenesis come from studies using skin as the tar-
get tissue. Furthermore, in terms of two-stage skin
carcinogenesis, most of the data are based on studies
that used a PAH as the initiator with croton oil or a
phorbol ester as the promoter (3,9). Under these con-
Table 9. Binding of 7,12-dimethylbenz[a]anthracene to the DNA
in the skin of mice of different strains.a
DMBA bound (pmole/mg DNA) in mouse skin
Strains 12 hr 24 hr 96 hr 192 hr
C57BL/6 22.0 52.4 19.2 8.3
DBA/2 30.5 41.0 19.0 10.5
Swiss 21.5 40.2 18.2 9.8
aModified from Phillips et al. (45).
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ditions, mice are much more sensitive than hamsters
and rats (3). It is possible that, if a different initiator
and/or promoterwere used, the sensitivitytotwo-stage
carcinogenesis in various species could be quite differ-
ent.
DiGiovanni et al. (48) have examined the sensitivity
of SENCAR, DBA/2, and C57BL/6 mice to skin tumor
promotion by TPA (12-O-tetradecanoylphorbol-13-ace-
tate). Their results, as well as those of others (46,49),
have shown that SENCAR mice are more sensitive to
TPA promotion than DBA/2 mice if DMBA (dimethyl-
benzanthracene) is used as the initiator. However,
DiGiovanni et al. (48) have also found that the DBA/2
mice are as sensitive to TPA promotion as SENCAR
mice if a direct-acting carcinogen such as N-methyl-N-
nitroso-N'-nitroguanidine (MNNG) is used as the ini-
tiator. Using either DMBA or MNNG, the C57BL/6
mice were resistant to TPApromotion (48). In addition,
DiGiovanni and co-workers (48) have also found that
susceptibility toTPApromotion appears to beinherited
as an autosomal dominant trait in crosses between
C57BL/6 and DBA/2 mice. Furthermore, susceptibility
to liver tumor induction in various mouse strains and
hybrids also appears to be related to tumor promotion
(47,50).
It should be emphasized that SENCAR mice are sen-
sitive to complete carcinogenesis as well as totwo-stage
carcinogenesis (9), whereas C57BL/6 mice are very re-
fractory to two-stage skin carcinogenesis by BP-TPA.
Even high initiating doses ofBP (1600 nmole) and high
promoting doses ofTPA (10 ptg) are very ineffective in
causing skin tumors in this strain; however, C57BL/6
mice do respond to BP by complete carcinogenesis (49).
This unequal susceptibility to complete and two-stage
carcinogenesis within a stock or strain ofmice strongly
suggests that the promotional stages of complete and
two-stage carcinogenesis aredissimilar. Inaddition, dif-
ferences in sensitivity to initiation and promotion be-
tweenmice may be due to alterations inthepromotional
stage of two-stage carcinogenesis. Benzoyl peroxide is
an effective promoter in C57BL/6 and SENCAR mice
when using DMBA as the initiator. In the DMBA-ben-
zoyl peroxide experiments, SENCAR and C57BL/6 an-
imals have similar tumor responses (49).
In order to understand the differences in suscepti-
bility to TPA promotion in SENCAR and C57BL/6
mice, Slaga and co-workers (22) examined a number of
biochemical and morphological responses assumed to be
markers for skin tumor promotion. Although after a
single topical treatment with TPA to SENCAR and
C57BL/6 mice there were some differences in hyper-
plasia, dark cells, and ornithine decarboxylase activity,
the differences were not great enough to account for
the difference intumorresponse (22). Furthermore, the
skin of both mice contains specific receptors for TPA
(22,51). TPA may not be an effective promoter in
C57BL/6 mice because this strain lacks the ability to
induce a sustained hyperplasia after repetitive TPA
treatment (9). Sisskin et al. (52) have shown that the
hamster (a species that is refractory to two-stage car-
cinogenesis) responds to a single treatment ofTPA but
loses responsiveness to repetitive treatment. These lat-
ter observations suggest the presence of an adaptive
metabolizing enzyme for TPA.
Conclusion
Many factors at the molecular level appear to be in-
volved in the inter- and intraspecies differences, in ad-
dition to organ differences, in carcinogenesis. Figure 4
summarizes the sequence of major events in chemical
carcinogenesis that can cause species and organ differ-
ences in response to a given carcinogen. The following
factors appearto play acriticalrolein species and organ
differences: the overall balance of metabolic activation
and detoxification of a carcinogen, the level and per-
sistence of DNA damage, repair processes, and tumor
promotion.
Although the level of response of a given chemical
carcinogen may be influenced by differences in meta-
bolic activation and/or detoxification, most studies have
only revealed subtle differences in metabolism. It is
quite remarkable that the major DNA adducts from
several activated carcinogens have been found tobe the
same in target tissues from various species, including
man; however, little is known about the importance of
DNA adducts that appear in smaller amounts. DNA
repair processes play important roles in species and
organ responses to chemical carcinogens. Although the
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FIGURE 4. A schematic illustratingthe major critical events in mul-
tistage carcinogenesis that are associated with organ and species
differences.
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results are inconclusive, it appears that persistent ad-
ducts from several classes of chemical carcinogens are
critical in the induction ofcancerin various species. The
susceptibility totwo-stage skin and livercarcinogenesis
in stocks and strains ofmice appears to be more closely
related to tumor promotion than the interaction of the
initiator with DNA or its removal. However, present
understanding ofthe critical events in tumorpromotion
is incomplete.
Overall, ifany chemical is found to be carcinogenic in
at least one species and its binding to DNA or its re-
moval from DNA is similar in target tissues of exper-
imental animals and humans, then there is a high prob-
ability that the compound will be carcinogenic to hu-
mans; this is obviously not true for carcinogenic com-
pounds that do not bind to DNA. In this case, if the
chemical is carcinogenic in at least two species and if
we do not have any consistent biochemical marker(s),
then we must assume it would have a high probability
ofcausing cancer in humans. Further comparative car-
cinogenesis studies are critically needed in order to ef-
fectivelyextrapolate carcinogenic potencydatafromex-
perimental animals to humans.
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